A. In March 2005 Cardiovascular Biotherapeutics (CVBT) was valued at $1,800,000,000. Under Dan Montano’s leadership (CEO / Chairman) it was delisted in 2012 at a value of $40,000,000.
Forbes says a CEO should above all protect investor share value
Daniel C. Montano tops our list of CEOs that fails time and again to provide returns while living off investor’s money. Now mired in legal and financial trouble, the truth about Dan Montano is finally reaching the public market where potential investors can make better and more informed decisions before putting their money at risk.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.